These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 37657939)

  • 21. Are there morphological differences between Parkinson's disease-dementia and dementia with Lewy bodies?
    Jellinger KA
    Parkinsonism Relat Disord; 2022 Jul; 100():24-32. PubMed ID: 35691178
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of Longitudinal β-Amyloid Accumulation Determined by Positron Emission Tomography With Clinical and Cognitive Decline in Adults With Probable Lewy Body Dementia.
    Nedelska Z; Schwarz CG; Lesnick TG; Boeve BF; Przybelski SA; Lowe VJ; Kremers WK; Gunter JL; Senjem ML; Graff-Radford J; Ferman TJ; Fields JA; Knopman DS; Petersen RC; Jack CR; Kantarci K
    JAMA Netw Open; 2019 Dec; 2(12):e1916439. PubMed ID: 31790563
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Galantamine for Alzheimer's disease.
    Olin J; Schneider L
    Cochrane Database Syst Rev; 2002; (3):CD001747. PubMed ID: 12137632
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Plasma pTau181 Predicts Clinical Progression in a Phase 2 Randomized Controlled Trial of the 11β-HSD1 Inhibitor Xanamem® for Mild Alzheimer's Disease.
    Taylor J; Jaros M; Chen C; Harrison J; Hilt D
    J Alzheimers Dis; 2024; 100(1):139-150. PubMed ID: 38848180
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The combined effect of amyloid-β and tau biomarkers on brain atrophy in dementia with Lewy bodies.
    Abdelnour C; Ferreira D; Oppedal K; Cavallin L; Bousiges O; Wahlund LO; Hort J; Nedelska Z; Padovani A; Pilotto A; Bonanni L; Kramberger MG; Boada M; Westman E; Pagonabarraga J; Kulisevsky J; Blanc F; Aarsland D
    Neuroimage Clin; 2020; 27():102333. PubMed ID: 32674011
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prodromal Dementia With Lewy Bodies: Clinical Characterization and Predictors of Progression.
    van de Beek M; van Steenoven I; van der Zande JJ; Barkhof F; Teunissen CE; van der Flier WM; Lemstra AW
    Mov Disord; 2020 May; 35(5):859-867. PubMed ID: 32048343
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gray matter atrophy in dementia with Lewy bodies with and without concomitant Alzheimer's disease pathology.
    van der Zande JJ; Steenwijk MD; Ten Kate M; Wattjes MP; Scheltens P; Lemstra AW
    Neurobiol Aging; 2018 Nov; 71():171-178. PubMed ID: 30149288
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dementia with Lewy bodies.
    McKeith IG; Burn DJ; Ballard CG; Collerton D; Jaros E; Morris CM; McLaren A; Perry EK; Perry R; Piggott MA; O'Brien JT
    Semin Clin Neuropsychiatry; 2003 Jan; 8(1):46-57. PubMed ID: 12567332
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness of acetylcholinesterase inhibitors: diagnosis and severity as predictors of response in routine practice.
    Van Der Putt R; Dineen C; Janes D; Series H; McShane R
    Int J Geriatr Psychiatry; 2006 Aug; 21(8):755-60. PubMed ID: 16906631
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Plasma Phosphorylated Tau181 and Amyloid-β42 in Dementia with Lewy Bodies Compared with Alzheimer's Disease and Cognitively Healthy People.
    Yu Y; Xia X; Meng X; Li D; Qin Q
    J Alzheimers Dis; 2023; 95(1):161-169. PubMed ID: 37482995
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A comparison of the efficacy of donepezil in Parkinson's disease with dementia and dementia with Lewy bodies.
    Thomas AJ; Burn DJ; Rowan EN; Littlewood E; Newby J; Cousins D; Pakrasi S; Richardson J; Sanders J; McKeith IG
    Int J Geriatr Psychiatry; 2005 Oct; 20(10):938-44. PubMed ID: 16163744
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial.
    Emre M; Tsolaki M; Bonuccelli U; Destée A; Tolosa E; Kutzelnigg A; Ceballos-Baumann A; Zdravkovic S; Bladström A; Jones R;
    Lancet Neurol; 2010 Oct; 9(10):969-77. PubMed ID: 20729148
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies.
    Bousiges O; Cretin B; Lavaux T; Philippi N; Jung B; Hezard S; Heitz C; Demuynck C; Gabel A; Martin-Hunyadi C; Blanc F
    J Alzheimers Dis; 2016; 51(4):1069-83. PubMed ID: 26923009
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Racial Disparity in Cerebrospinal Fluid Amyloid and Tau Biomarkers and Associated Cutoffs for Mild Cognitive Impairment.
    Garrett SL; McDaniel D; Obideen M; Trammell AR; Shaw LM; Goldstein FC; Hajjar I
    JAMA Netw Open; 2019 Dec; 2(12):e1917363. PubMed ID: 31834392
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacologic therapy of dementia with Lewy bodies.
    Kaufer DI
    J Geriatr Psychiatry Neurol; 2002; 15(4):224-32. PubMed ID: 12489919
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Galantamine for Alzheimer's disease.
    Olin J; Schneider L
    Cochrane Database Syst Rev; 2001; (4):CD001747. PubMed ID: 11687119
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparisons of clinical symptoms in biomarker-confirmed Alzheimer's disease, dementia with Lewy bodies, and frontotemporal dementia patients in a local memory clinic.
    Shea YF; Ha J; Chu LW
    Psychogeriatrics; 2015 Dec; 15(4):235-41. PubMed ID: 25533477
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential diagnostic value of total alpha-synuclein assay in the cerebrospinal fluid between Alzheimer's disease and dementia with Lewy bodies from the prodromal stage.
    Bousiges O; Philippi N; Lavaux T; Perret-Liaudet A; Lachmann I; Schaeffer-Agalède C; Anthony P; Botzung A; Rauch L; Jung B; de Sousa PL; Demuynck C; Martin-Hunyadi C; Cretin B; Blanc F
    Alzheimers Res Ther; 2020 Sep; 12(1):120. PubMed ID: 32993772
    [TBL] [Abstract][Full Text] [Related]  

  • 39. TDP-43 pathology in Alzheimer's disease, dementia with Lewy bodies and ageing.
    McAleese KE; Walker L; Erskine D; Thomas AJ; McKeith IG; Attems J
    Brain Pathol; 2017 Jul; 27(4):472-479. PubMed ID: 27495267
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Olfactory function and neuropsychological profile to differentiate dementia with Lewy bodies from Alzheimer's disease in patients with mild cognitive impairment: A 5-year follow-up study.
    Yoon JH; Kim M; Moon SY; Yong SW; Hong JM
    J Neurol Sci; 2015 Aug; 355(1-2):174-9. PubMed ID: 26076880
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.